Global Lutetium-177 Market Size is valued at USD 2.11 Bn in 2024 and is predicted to reach USD 7.41 Bn by the year 2034 at a 11.6% CAGR during the forecast period for 2025 to 2034.
Lutetium-177 Market Size, Share & Trends Analysis Distribution by Application (Oncology, Non-Oncology), Type (No-Carrier-Added (NCA) Lu-177, Carrier-Added (CA) Lu-177), Product Type (Approved Drugs, Pipeline Drugs, Investigational Drugs), Scale of Operation (Preclinical, Clinical, Commercial), End-user (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Research Institutions/CROs), Production(Reactor-Based, Cyclotron-Based), Technology (Targeting Ligands, Production Innovations, Combination Therapies) and Segment Forecasts, 2025 to 2034.
Lutetium-177 (Lu-177) is a radioactive isotope employed in targeted radionuclide therapy for neuroendocrine tumors and prostate cancer. Being a medium-energy beta emitter with a half-life of 6.7 days, it targets regional radiation with minimal injury to normal tissues. Lu-177 is manufactured in two types: Non-Carrier-Added (NCA) Lu-177, which has high purity and high specific activity, a requirement for precision medicine, and Carrier-Added (CA) Lu-177, a cheaper but lower specific activity type with proven production processes.
It is used in peptide receptor radionuclide therapy (PRRT) and PSMA-directed therapies, as well as in radiopharmaceutical research and nuclear medicine. One of the main drivers of the Lu-177 market is the growing need for targeted radiotherapy solutions in the face of escalating global cancer incidence. With healthcare providers looking for effective treatments with fewer side effects, the precision and effectiveness of Lu-177 make it a go-to option. Moreover, advancements in nuclear medicine and supportive regulatory frameworks also propel its uptake, ensuring sustained market growth and innovation in cancer therapy.
Some of the Key Players in Lutetium-177 Market:
The lutetium-177 market is segmented by application, type, product type, scale of operation, end user, production, technology. By application, the market is segmented into oncology, non-oncology. Oncology is sub segmented mCRPC, NETs, RCC, and other cancers. Non-oncology is sub segmented into arthritis, other. By type market is segmented into carrier-added lutetium-177, no-carrier-added lutetium-177.
By Product type the market is segmented into approved drugs, pipeline drugs, investigational drugs. Approved Drugs is sub segmented into, Pluvicto (Pro), Lutathera (Pro). By scale of operation the market is segmented into preclinical, clinical, commercial. By end-user the market is segmented into hospitals & clinics, pharmaceutical & biotechnology companies, research institutions/CROs. By production the market is segmented into reactor-based, cyclotron-based. By technology, the market is segmented into targeting ligands, production innovations, combination therapies.
The market for lutetium-177 (Lu-177) is largely driven by targeting ligands, which allow beta radiation to be precisely delivered to cancer cells while avoiding damage to healthy tissue. By attaching to tumor-specific receptors, these ligands—peptides, antibodies, or small molecules—increase treatment effectiveness and reduce adverse effects. Additionally, their application facilitates a theranostic strategy by enabling imaging to find qualified patients prior to treatment. New ligands for other tumors have been developed as a result of the successful treatment of prostate and neuroendocrine cancers, increasing applications and speeding up market expansion.
The No-Carrier-Added (NCA) Lutetium-177 segment is experiencing significant growth in the Lu-177 market due to its high purity and superior specific activity. Produced via the indirect method by irradiating ytterbium-176 (Yb-176), NCA Lu-177 lacks Lu-177m, resulting in a purer product with enhanced therapeutic concentrations and reduced radioactive waste. Its higher efficacy and minimal side effects make it the preferred choice for targeted therapies such as peptide receptor radionuclide therapy (PRRT) and PSMA-targeted treatments, driving its increasing adoption in precision cancer treatment.
North America dominates the Lutetium-177 (Lu-177) market due to its sophisticated healthcare infrastructure, high incidence of cancer, and robust research and development efforts. The region's advanced medical facilities enable the extensive use of Lu-177 therapies for the treatment of neuroendocrine tumors and prostate cancer. North America is also home to many pharmaceutical and biotech firms involved in cancer research, which encourages innovation and drives the uptake of Lu-177 in targeted radionuclide therapies.
| Report Attribute | Specifications |
| Market size value in 2024 | USD 2.11 Bn |
| Revenue forecast in 2034 | USD 7.41 Bn |
| Growth Rate CAGR | CAGR of 11.6% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2024 to 2034 |
| Historic Year | 2021 to 2023 |
| Forecast Year | 2024-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Application, Type, Product Type, Scale of Operation, End User, Production, Technology and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Novartis AG, Curium, Telix Pharmaceuticals, ITM Isotope Technologies, Eli Lilly (via POINT Biopharma), Radiopharm Theranostics, Advanced Accelerator Applications (AAA), Evergreen Theragnostics, Nusano Inc., Nordic Nanovector |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Lutetium-177 Market -
Lutetium-177 Market by Application-
Lutetium-177 Market by Type-
Lutetium-177 Market by Product Type-
Lutetium-177 Market by Scale of Operation-
Lutetium-177 Market by End-user-
Lutetium-177 Market by Production-
Lutetium-177 Market by Technology-
Lutetium-177 Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.